期刊档案 · Medicine-Oncology
ImmunoOncology and Technology
ISSN 2590-0188 · Elsevier · United Kingdom
ImmunoOncology and Technology 完全开放获取，APC 约 3,490 美元，出版商公布投稿到接收约 153 天，2025 年发文 407 篇，Scopus 收录。
研究范围
研究范围与定位
ImmunoOncology and Technology 由 Elsevier 出版。按 OpenAlex 近年发文统计，该刊主要发表 Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Lung Cancer Treatments and Mutations 等主题的论文，这 3 个主题约占 57.2%，主导子领域为 Oncology、Immunology。（根据 OpenAlex 主题统计与中科院分区数据生成）
Immuno-Oncology and Technology (IOTECH) is sister journal to Annals of Oncology and ESMO Open and part of the European Society for Medical Oncology's portfolio of world-class journals. By publishing high quality original research articles, reviews, perspectives, technology explained papers, letters to the editor and editorials, IOTECH aspires to provide a forum for todays' leaders in the field of Immuno-Oncology.IOTECH is published quarterly and led by Co-Editors in Chief, Professor John Haanen and Professor Sherene Loi and an international team of expert Editors and Editorial Board members. It publishes pre-clinical and clinical studies covering natural and therapy-induced innate and adaptive immune responses against solid and haematological cancers. In addition, the journal has a strong focus on technological developments in Immuno-Oncology and seeks to highlight technological advances that decipher and improve clinical outcomes.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Oncology
主编 Sherene Loi出版商官网
编委会国家分布：未见中国大陆编委；主要国家 美国 11、英国 9、瑞士 7、西班牙 2、加拿大 2（共 41 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Cancer Immunotherapy and BiomarkersMedicine37.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology13.5%
- Lung Cancer Treatments and MutationsMedicine6.5%
- T-cell and B-cell ImmunologyImmunology and Microbiology5.3%
- CAR-T cell therapy researchMedicine4.1%
- Lung Cancer Research StudiesMedicine3.7%
- Cutaneous Melanoma Detection and ManagementMedicine3.3%
- Lung Cancer Diagnosis and TreatmentMedicine3.2%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
CiteScore 分区（Scopus，2026 年 6 月版）
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Oncology | Q1 | 69/428 | 83% |
| Immunology and Allergy | Q1 | 48/234 | 79% |
Scopus 按 CiteScore 在每个学科内为期刊排名，百分位 75 及以上为 Q1，每 25 为一档；与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
PubMed出版商官网
其他：Crossref
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 8.6LetPub ·
- CiteScore（出版商公布）
- 8.6出版商官网 ·
- SJR 2026-06
- 1.88LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 54OpenAlex ·
- 两年平均被引
- 0.48OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 1,248 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 28 | 28 | 523 |
| 2025 | 407 | 407 | 580 |
| 2024 | 255 | 255 | 464 |
| 2023 | 229 | 229 | 321 |
| 2022 | 270 | 270 | 126 |
| 2021 | 19 | 19 | 72 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
出版商公布的审稿周期 期刊官网自述数据
153 天投稿到接收 · 投稿社区反馈约 29 周
出版商统计口径以官网为准；本刊近 24 个月的文章日期尚未获得，因此以官方数据为准。
各来源数据
- 平均审稿速度（社区反馈）
- 29 WeeksLetPub ·
- 投稿到接收
- 153 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 29 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 3,490 | 有 | CC BY-NC-ND | |
| OpenAlex | USD 3,340 / EUR 3,050 / GBP 2,670 / JPY 414,260 | — | — | |
| LetPub | EUR 2,750 | 有 | — | |
| 出版商官网 | USD 3,490 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点2 项，摘自作者指南
- 稿件模板
- 提供 LaTeX 模板
- 图文摘要
- 可选
接收的文章类型15 种，含篇幅限制
- commentarysals for future avenues of exploration. Commentaries are generally commissioned by the Editors and should be a maximum of 1,500 words and have a maximum of ten …正文 ≤ 1,500 词
- correspondenceOn topics of current interest or commenting upon material previously or simultaneously published in the journal. They should be limited to 500 words and may inc…正文 ≤ 500 词
- editorialOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…正文 ≤ 1,500 词
- editorialsEditorials (maximum 1,500 words)未说明篇幅
- meta-analysisOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- narrative reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- original articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…正文 ≤ 3,500 词
- original articlesOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)未说明篇幅
- original researchOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- research articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- review articleOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…正文 ≤ 4,000 词
- review articlesReview Articles (maximum 4,000 words)未说明篇幅
- systematic reviewOriginal Articles (maximum of 3,500 words from the beginning of the Introduction to the end of the Discussion)Original articles should describe original researc…未说明篇幅
- technology explained'Technology explained' articles should be approximately 2,000 words in length未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. AI and AI-assisted technologies should not be used t…
原文 ↗出版商官网 ·- 作者资格 Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
原文 ↗出版商官网 ·- 利益冲突 Declaration of Potential Conflicts of Interest
Any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated - including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition - should…
原文 ↗出版商官网 ·- 出版伦理
Ethics in publishing: refer to Elsevier's information on Ethics in publishing. 模型摘要
Please see our information on Ethics in publishing.
原文 ↗出版商官网 ·- 许可与版权 Copyright
Copyright: authors complete a License Agreement upon acceptance; third-party reuse determined by chosen user license. 模型摘要
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. More information.
原文 ↗出版商官网 ·- 开放获取 Open access
Please visit our Open Access page for more information about open access publishing in this journal.
原文 ↗出版商官网 ·- 同行评审 Peer Review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
原文 ↗出版商官网 ·- 预印本 Preprints
Preprints can be shared anywhere at any time; sharing will not count as prior publication. 模型摘要
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2590-0188
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
常见问题
关于 ImmunoOncology and Technology 的常见问题
ImmunoOncology and Technology 的审稿周期多长？
出版商公布的投稿到接收时间约为 153 天；投稿社区反馈的平均审稿速度为约 29 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
ImmunoOncology and Technology 的投稿格式要求是什么？
据期刊作者指南：稿件模板：提供 LaTeX 模板；图文摘要：可选。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
ImmunoOncology and Technology 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 41 位编委中，没有中国大陆学者；人数最多的国家是 美国（11 位）、英国（9 位）、瑞士（7 位）。统计按编委会页面列出的机构国家计，仅供参考。
ImmunoOncology and Technology 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，ImmunoOncology and Technology 被 Scopus、DOAJ 收录。期刊官网自述还被 PubMed 收录，该清单未与各数据库逐一核对。
ImmunoOncology and Technology 是开放获取期刊吗？版面费多少？
ImmunoOncology and Technology 为完全开放获取。APC 约 3,490 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。